Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
M Aardoom, Gigi Veereman, Lissy de Ridder
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2529-2529
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review
Zachary Green, R. Mark Beattie, James J. Ashton
Translational Pediatrics (2023) Vol. 12, Iss. 10, pp. 1853-1874
Open Access | Times Cited: 6
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America
Basavaraj Kerur, Karoline Fiedler, Marisa G. Stahl, et al.
Journal of Pediatric Gastroenterology and Nutrition (2022) Vol. 75, Iss. 1, pp. 64-69
Closed Access | Times Cited: 10
Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study
M. Classen, Jan de Laffolie, Martin Claßen, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 10
Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease
Lauren V. Collen, Vanessa Mitsialis, David Y. Kim, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 9, pp. 1443-1453
Closed Access | Times Cited: 5
Ameliorative Effect of Heat-Killed Lactobacillus plantarum L.137 and/or Aloe vera against Colitis in Mice
Heba Ismaeil, Walied Abdo, Said Amer, et al.
Processes (2020) Vol. 8, Iss. 2, pp. 225-225
Open Access | Times Cited: 15
Pharmacogenetics of trough serum anti‐TNF levels in paediatric inflammatory bowel disease
Sara Salvador‐Martín, Gemma Pujol‐Muncunill, Ferrán Bossacoma, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 2, pp. 447-457
Open Access | Times Cited: 15
Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
Kaija-Leena Kolho
Frontiers in Pediatrics (2021) Vol. 8
Open Access | Times Cited: 13
Inflammation-oriented montmorillonite adjuvant enhanced oral delivery of anti-TNF-α nanobody against inflammatory bowel disease
Baolian Huang, Te Yin, Shuilian Fu, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 37
Closed Access | Times Cited: 1
Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
Eloísa Martins da Silva, Victor Yuji Yariwake, Renan Willian Alves, et al.
Peptides (2022) Vol. 155, pp. 170834-170834
Closed Access | Times Cited: 8
Inflammatory Bowel Disease in Children
Asha Jois, George Alex
The Indian Journal of Pediatrics (2023) Vol. 91, Iss. 5, pp. 490-498
Closed Access | Times Cited: 4
Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis
Ma’in Abumuhfouz, Anas Al-sadi, Waseem Umer, et al.
Clinical Case Reports (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 1
Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia‐Feng Wu, Hsu‐Heng Yen, Horng‐Yuan Wang, et al.
Intestinal Research (2024) Vol. 22, Iss. 3, pp. 250-285
Open Access | Times Cited: 1
A derivative of tanshinone IIA and salviadione, 15a, inhibits inflammation and alleviates DSS-induced colitis in mice by direct binding and inhibition of RIPK2
Chenghong Hu, Yue Chen, Tianyang Jin, et al.
Acta Pharmacologica Sinica (2024)
Closed Access | Times Cited: 1
Ellipticine Conveys Protective Effects to Lipopolysaccharide-Activated Macrophages by Targeting the JNK/AP-1 Signaling Pathway
Lixing Tian, Xiaoyu Li, Xin Tang, et al.
Inflammation (2019) Vol. 43, Iss. 1, pp. 231-240
Closed Access | Times Cited: 13
Biological therapy in pediatric age
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, et al.
Pharmacological Research (2020) Vol. 161, pp. 105120-105120
Closed Access | Times Cited: 12
Treatment patterns of anti‐tumour necrosis factor‐alpha and prognosis of paediatric and adult‐onset inflammatory bowel disease in Korea: a nationwide population‐based study
Young June Choe, Kyungdo Han, Jung Ok Shim
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 980-988
Open Access | Times Cited: 7
Postbiotic muramyl dipeptide alleviates colitis via activating autophagy in intestinal epithelial cells
Yaying You, Yongtao Xiao, Ying Lu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
A Review of Selected IBD Biomarkers: From Animal Models to Bedside
Emiko Mizoguchi, Renuka Subramaniam, Toshiyuki Okada, et al.
Diagnostics (2021) Vol. 11, Iss. 2, pp. 207-207
Open Access | Times Cited: 10
Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients
Mirko Di Ruscio, Ilaria Tinazzi, Angela Variola, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 12, pp. 5809-5813
Closed Access | Times Cited: 9
Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation
Jiří Bronský, Ivana Čopová, Denis Kazeka, et al.
Clinical and Translational Gastroenterology (2022) Vol. 13, Iss. 5, pp. e00490-e00490
Open Access | Times Cited: 6
Uncovering Novel Pre-Treatment Molecular Biomarkers for Anti-TNF Therapeutic Response in Patients with Crohn’s Disease
Min Seob Kwak, Jae Myung, Jung Won Jeon, et al.
Journal of Functional Biomaterials (2022) Vol. 13, Iss. 2, pp. 36-36
Open Access | Times Cited: 6
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
M. Classen, André Hoerning
Children (2023) Vol. 10, Iss. 4, pp. 634-634
Open Access | Times Cited: 3
A Patient with Adalimumab-Induced Refractory Paradoxical Palmoplantar Pustulosis Was Successfully Treated by Ixekizumab: A Case Report
Xinyi Shao, Jianxia Xiong, Aijun Chen, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 879-881
Open Access | Times Cited: 3
Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
Stefania Cheli, Diego Savino, Francesca Penagini, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1834-1834
Open Access | Times Cited: 3
TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case
Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anna L. Arakelyan, et al.
Вопросы современной педиатрии (2023) Vol. 22, Iss. 5, pp. 470-476
Open Access | Times Cited: 3

Scroll to top